MARKET EYE-India's Sun Pharma gains on higher prices for drugs

Fri Feb 22, 2013 12:45pm IST

Related Topics

Stocks

   

* Shares in Sun Pharmaceutical Industries gain 1.5 percent after Credit Suisse said the drug maker's subsidiary Taro Pharmaceutical Industries has pushed through price increases in three products last week, citing industry checks. * Credit Suisse estimates those three drugs account for 35 percent of Taro U.S. sales. * The price increases raise sustainable sales estimates for Taro to $680 million versus $640 million earlier for FY 2015, the investment bank adds. * Credit Suisse maintains its "outperform" rating on the stock and raises its target price to 900 rupees from 840 rupees, in part by factoring higher sales estimates for Taro. (abhishek.vishnoi@thomsonreuters.com /; abhishek.vishnoi.thomsonreuters.com@reuters.net)

FILED UNDER:

Economic Pulse

Reuters Showcase

S&P on Budget

S&P on Budget

Budget shows commitment to keep fiscal deficit low  Full Article | On Ratings 

PMI Data

PMI Data

Factory activity growth slows to five-month low in Feb  Full Article 

Fitch on Budget

Fitch on Budget

India's "less aspiring" fiscal consolidation strategy negative for ratings  Full Article 

Monetary Policy

Monetary Policy

Two policymakers see case for RBI rate cut - report  Full Article 

China Economy

China Economy

China Feb HSBC PMI at seven-month high but more rate cuts seen on the cards  Full Article 

Battling Apple

Battling Apple

Samsung unveils sleek new Galaxy phones  Full Article 

Moody's on Budget

Moody's on Budget

Budget "credit neutral" from a ratings perspective  Full Article 

On Rate Hike

On Rate Hike

Insight: Near Fed majority backs June liftoff Yellen hasn't yet endorsed  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage